^
Association details:
Biomarker:No biomarker
Cancer:Marginal Zone Lymphoma
Regimen: (cyclophosphamide + prednisone + Rituxan (rituximab) + vincristine)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Title:

Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Published date:
01/06/2020
Excerpt:
Summary of recommendations: Chemoimmunotherapy is recommended in patients with NMZL (e.g. R-bendamustine, R-CHOP, R-CVP) [IV, B].
DOI:
10.1016/j.annonc.2019.10.010
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Marginal Zone Lymphoma: Second-Line and subsequent therapy...CVP (cyclophosphamide, vincristine, prednisone) + Rituximab